Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort Study
PhD Xiaofeng Zhou, PhD Scott P Kelly, MD Caihua Liang, MS Ling Li, MS Rongjun Shen, BSN Heidi K Leister-Tebbe, PharmD Steven G Terra, PhD Michael Gaffney, PhD Leo Russo
doi:10.1101/2022.09.13.22279908
Objectives: The aim of this analysis was to describe nirmatrelvir/ritonavir real-world effectiveness in preventing hospitalization among high-risk US COVID-19 patients during SARS-CoV-2 Omicron predominance. Design: An ongoing population-based cohort study with retrospective and prospective collection of electronic healthcare data in the United States. Methods: Data for this analysis were collected from the US Optum® de-identified COVID-19 Electronic Health Record (EHR) dataset during December 22, 2021−June 8, 2022. Key eligibility criteria for inclusion in the database analysis were ≥12-years-old; positive SARS-CoV-2 test, COVID-19 diagnosis, or nirmatrelvir/ritonavir prescription; and high risk of severe COVID-19 based on demographic/clinical characteristics. Potential confounders between groups were balanced using propensity score matching (PSM). Immortal time bias was addressed. Outcome measures: Hospitalization rates within 30 (primary analysis) or 15 (sensitivity analysis) days from COVID-19 diagnosis overall and within subgroups were evaluated. Results: Before PSM, the nirmatrelvir/ritonavir group (n=2811) was less racially diverse, older, and had higher COVID-19 vaccination rates and a greater number of comorbidities than the nonnirmatrelvir/ritonavir group (n=194,542). Baseline characteristics were well balanced across groups (n=2808 and n=10,849, respectively) after PSM. Incidence of hospitalization (95% CI) within 30 days was 1.21% (0.84%−1.69%) for the nirmatrelvir/ritonavir group and 6.94% (6.03%−7.94%) for the nonnirmatrelvir/ritonavir group, with a hazard ratio (95% CI) of 0.16 (0.11−0.22; 84% relative risk reduction). Incidence within 15 days was 0.78% (0.49%−1.18%) for the nirmatrelvir/ritonavir group and 6.54% (5.65%−7.52%) for the non-nirmatrelvir/ritonavir group; hazard ratio 0.11 (0.07−0.17; 89% relative risk reduction). Nirmatrelvir/ritonavir was effective in African American patients (hazard ratio, 0.35 [0.15−0.83]; 65% relative risk reduction). Relative risk reductions were comparable with overall results across ages and among vaccinated patients.
Conclusions: Real-world nirmatrelvir/ritonavir effectiveness against hospitalization during the Omicron era supports EPIC-HR efficacy among high-risk patients. Future research should confirm these early realworld results and address limitations.
Competing Interests All authors are employees of Pfizer Inc and may hold stock or stock options.
Data Sharing Statement Upon request, and subject to review, Pfizer will provide the summary data that support the findings of this study.
References
Allen, Johnson, Haddock, Game Changer: Paxlovid Reduces Hospitalizations and Saves Lives
Arbel, Sagy, Hoshen, Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge, N Engl J Med,
doi:10.1056/NEJMoa2204919Austin, An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies, Multivariate Behav Res,
doi:10.1080/00273171.2011.568786Dal-Re, Becker, Bottieau, Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach, Lancet Infect Dis,
doi:10.1016/S1473-3099(22)00119-0Docherty, Harrison, Green, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study, BMJ,
doi:10.1136/bmj.m1985Griffin, Brennan-Rieder, Ngo, The Importance of Understanding the Stages of COVID-19 in Treatment and Trials, AIDS Rev,
doi:10.24875/AIDSRev.200001261Hammond, Leister-Tebbe, Gardner, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Hodcroft, CoVariants: SARS-CoV-2 Mutations and Variants of Interest
Htoo, Measer, Orr, Evaluating Confounding Control in Estimations of Influenza Antiviral Effectiveness in Electronic Health Plan Data, Am J Epidemiol,
doi:10.1093/aje/kwac020Iuliano, Brunkard, Boehmer, Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods -United States, December 2020-January 2022, MMWR Morb Mortal Wkly Rep,
doi:10.15585/mmwr.mm7104e4Jh, Londhe, Brooks, Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study, BMJ Open,
doi:10.1136/bmjopen-2021-055137Ko, Danielson, Town, Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System, Clin Infect Dis,
doi:10.1093/cid/ciaa1419Levesque, Hanley, Kezouh, Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes, BMJ,
doi:10.1136/bmj.b5087Malden, Hong, Lewin, Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment -California, December 2021, MMWR Morb Mortal Wkly Rep,
doi:10.15585/mmwr.mm7125e2Mude, Oguoma, Nyanhanda, Racial disparities in COVID-19 pandemic cases, hospitalisations, and deaths: A systematic review and meta-analysis, J Glob Health,
doi:10.7189/jogh.11.05015Najjar-Debbiny, Gronich, Weber, Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients, Clin Infect Dis,
doi:10.1093/cid/ciac443Norgaard, Ehrenstein, Vandenbroucke, Confounding in observational studies based on large health care databases: problems and potential solutions -a primer for the clinician, Clin Epidemiol,
doi:10.2147/CLEP.S129879Owen, Allerton, Anderson, An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19, Science,
doi:10.1126/science.abl4784Singh, Toussi, Hackman, Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir, Clin Pharmacol Ther,
doi:10.1002/cpt.2603Tai, Shah, Doubeni, The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States, Clin Infect Dis,
doi:10.1093/cid/ciaa815Toussi, Neutel, Navarro, Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment, Clin Pharmacol Ther,
doi:10.1002/cpt.2688Zhou, Rahme, Abrahamowicz, Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods, Am J Epidemiol,
doi:10.1093/aje/kwi307DOI record:
{
"DOI": "10.1101/2022.09.13.22279908",
"URL": "http://dx.doi.org/10.1101/2022.09.13.22279908",
"abstract": "<jats:p>Objectives: The aim of this analysis was to describe nirmatrelvir/ritonavir real-world effectiveness in preventing hospitalization among high-risk US COVID-19 patients during SARS-CoV-2 Omicron predominance.\nDesign: An ongoing population-based cohort study with retrospective and prospective collection of electronic healthcare data in the United States.\nMethods: Data for this analysis were collected from the US Optum de-identified COVID-19 Electronic Health Record (EHR) dataset during December 22, 2021 to June 8, 2022. Key eligibility criteria for inclusion in the database analysis were at least 12-years-old; positive SARS-CoV-2 test, COVID-19 diagnosis, or nirmatrelvir/ritonavir prescription; and high risk of severe COVID-19 based on demographic/clinical characteristics. Potential confounders between groups were balanced using propensity score matching (PSM). Immortal time bias was addressed.\nOutcome measures: Hospitalization rates within 30 (primary analysis) or 15 (sensitivity analysis) days from COVID-19 diagnosis overall and within subgroups were evaluated.\nResults: Before PSM, the nirmatrelvir/ritonavir group (n=2811) was less racially diverse, older, and had higher COVID-19 vaccination rates and a greater number of comorbidities than the non-nirmatrelvir/ritonavir group (n=194,542). Baseline characteristics were well balanced across groups (n=2808 and n=10,849, respectively) after PSM. Incidence of hospitalization (95% CI) within 30 days was 1.21% (0.84%, 1.69%) for the nirmatrelvir/ritonavir group and 6.94% (6.03%, 7.94%) for the non-nirmatrelvir/ritonavir group, with a hazard ratio (95% CI) of 0.16 (0.11, 0.22; 84% relative risk reduction). Incidence within 15 days was 0.78% (0.49%, 1.18%) for the nirmatrelvir/ritonavir group and 6.54% (5.65%, 7.52%) for the non-nirmatrelvir/ritonavir group; hazard ratio 0.11 (0.07, 0.17; 89% relative risk reduction). Nirmatrelvir/ritonavir was effective in African American patients (hazard ratio, 0.35 [0.15, 0.83]; 65% relative risk reduction). Relative risk reductions were comparable with overall results across ages and among vaccinated patients.\nConclusions: Real-world nirmatrelvir/ritonavir effectiveness against hospitalization during the Omicron era supports EPIC-HR efficacy among high-risk patients. Future research should confirm these early real-world results and address limitations.</jats:p>",
"accepted": {
"date-parts": [
[
2022,
9,
14
]
]
},
"author": [
{
"ORCID": "http://orcid.org/0000-0002-2109-0012",
"affiliation": [],
"authenticated-orcid": false,
"family": "Zhou",
"given": "Xiaofeng",
"sequence": "first"
},
{
"affiliation": [],
"family": "Kelly",
"given": "Scott P",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Liang",
"given": "Caihua",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Li",
"given": "Ling",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Shen",
"given": "Rongjun",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Leister-Tebbe",
"given": "Heidi",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Terra",
"given": "Steven G",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Gaffney",
"given": "Michael",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Russo",
"given": "Leo J",
"sequence": "additional"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2022,
9,
15
]
],
"date-time": "2022-09-15T03:25:22Z",
"timestamp": 1663212322000
},
"deposited": {
"date-parts": [
[
2022,
9,
15
]
],
"date-time": "2022-09-15T03:25:23Z",
"timestamp": 1663212323000
},
"group-title": "Infectious Diseases (except HIV/AIDS)",
"indexed": {
"date-parts": [
[
2022,
9,
15
]
],
"date-time": "2022-09-15T03:44:52Z",
"timestamp": 1663213492888
},
"institution": [
{
"name": "medRxiv"
}
],
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2022,
9,
14
]
]
},
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.1101/2022.09.13.22279908",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "246",
"original-title": [],
"posted": {
"date-parts": [
[
2022,
9,
14
]
]
},
"prefix": "10.1101",
"published": {
"date-parts": [
[
2022,
9,
14
]
]
},
"publisher": "Cold Spring Harbor Laboratory",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "http://medrxiv.org/lookup/doi/10.1101/2022.09.13.22279908"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subtitle": [],
"subtype": "preprint",
"title": "Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort Study",
"type": "posted-content"
}
